Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial

In the randomised phase 2 portion of this study, the addition of capecitabine to trastuzumab emtansine did not result in a statistically significant improvement in overall response rate (44% v 36% with trastuzumab emtansine alone; difference 8.2%; 90% CI, −4.5 to 20.9; p=0.34).


JAMA Oncology